# Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia

> **NCT00541554** · PHASE4 · UNKNOWN · sponsor: **Genovate Biotechnology Co., Ltd.,**

## Conditions studied

- Hyperprolactinemia
- Weight Gain
- Dyslipidemia

## Interventions

- **DRUG:** Abilify (aripiprazole)

## Key facts

- **NCT ID:** NCT00541554
- **Lead sponsor:** Genovate Biotechnology Co., Ltd.,
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-10
- **Primary completion:** —
- **Final completion:** 2009-02
- **Target enrollment:** — (—)
- **Last updated:** 2007-10-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00541554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00541554, "Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00541554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*